Ucbbiopharma Srl

Ucb Biopharma Sprl

David James McMillan

Terence Seward Baker

Patrick Downey

Kerry Louise Tyson

Daniel John Lightwood

David Edward Ormonde Knight

Georges Mairet-Coello

Jean-Philippe Courade

Robert Anthony Griffin

Lorenzo De Lichtervelde

Michael John Wright

Breda Twomey

Peter Charles Elliott

Neesha Dedi

Marco Kriek

John Robert Porter

Graham John Warrellow

Rikki Peter Alexander

Ralph Adams

Daniel Christopher Brookings

Stephen Edward Rapecki

Boris Kroeplien

Timothy John Norman

Alastair Lawson

James Philip O'Connell

Gareth Charles Glyndwr Davies

Gareth Davies

The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Anti-alpha-synuclein antibodies

This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

Gremlin-1 crystal structure and inhibitory antibody

The present invention relates to Tau-binding antibodies and binding fragments thereof.

Tau-binding antibodies

Anti-alpha synuclein antibodies

The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.

Gremlin-1 antibody

The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

Methods of identifying signaling modulators of the trimeric TNFa

Growing community of inventors

Slough, United Kingdom

David James McMillan